Performance History
| Key Stats | |
|---|---|
| Open | $1.63 |
| Prev. Close | $1.60 |
| EPS | -1.86 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | 47445440.00 |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.54 | 1.63 |
| 52 Week Range | 1.38 | 11.92 |
| Ratios | |
|---|---|
| P/B Ratio | 0.60 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | $0.00 |
| Earnings Growth % | -5.86% |
| EBITDA Margin % | - |
| ROE % | -61.38% |
| EPS | -1.86 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Immuneering Corporation (IMRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
- Headquarters
- Cambridge
- Employees
- 66
- Exchange
- NASDAQ
Keep an eye on Immuneering Corporation
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is Immuneering Corporation's (IMRX) price per share?
The current price per share for Immuneering Corporation (IMRX) is $1.57. The stock has seen a price change of -$0.03 recently, indicating a -1.88% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for Immuneering Corporation (IMRX)?
For Immuneering Corporation (IMRX), the 52-week high is $11.92, which is 659.24% from the current price. The 52-week low is $1.38, the current price is 13.77% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is Immuneering Corporation (IMRX) a growth stock?
Immuneering Corporation (IMRX) has shown an average price growth of 0.41% over the past three years. It has received a score of 42 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Immuneering Corporation as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is Immuneering Corporation (IMRX) stock price performance year to date (YTD)?
As of the latest data, Immuneering Corporation (IMRX) has a year-to-date price change of -78.55%. Over the past month, the stock has experienced a price change of -18.02%. Over the last three months, the change has been -76.57%. Over the past six months, the figure is -70.27%.
Is Immuneering Corporation (IMRX) a profitable company?
Immuneering Corporation (IMRX) has a net income of -$53.47M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$58.41M. Furthermore, the EBITDA is -$58.69M.
What is the market capitalization of Immuneering Corporation (IMRX)?
Immuneering Corporation (IMRX) has a market capitalization of $47.45M. The average daily trading volume is 234.61K, indicating the stock's liquidity and investor engagement.
News
Apple’s iPad Accounted for Nearly 2 in Every 5 Tablets Shipped Globally in 2023
Boeing’s Aircraft Deliveries to North America Hit 22-Year High at 293 Units
NYCB to Boost Capital and Liquidity Through $5 Billion Loan Sale to JPMorgan Chase
Gemini Ultra Training Costs in 2023 Neared $200 Million, More Than 2X GPT4
Microsoft Leads in Carbon Dioxide Removal (CDR) Credit Purchases, Acquiring 6.6M Tonnes, Surpassing All Other Buyers Combined
SoftBank’s Profitability Surges Amid AI Investment Boom
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.